Supernus Pharmaceuticals | SUPN - Ebit


Supernus Pharmaceuticals reported $-60.18M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Abbott USD 2.54B 358M Dec/2025
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Aurora Cannabis CAD -44.75M 27.14M Sep/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Canopy Growth CAD -14.3M 17.19M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
Supernus Pharmaceuticals USD -60.18M 72.33M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Xeris Pharmaceuticals USD 7.89M 2.46M Sep/2025